Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2-DM1 ADC B003

An antibody-drug conjugate (ADC) consisting of a recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC), with potential antineoplastic activity. Upon administration of B003, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics, inhibiting cell division and the proliferation of cancer cells that overexpress HER2.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC B003
anti-HER2-DM1 antibody-drug conjugate B003
recombinant humanized anti-HER2 monoclonal antibody-MCC-DM1 B003
Code name:B 003
B-003
B003
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search